Technegas Kit is a drug owned by Cyclomedica Australia Pty Ltd. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 24, 2031. Details of Technegas Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7722856 | Process For The Production Of A Radioactive Aerosol |
Feb, 2031
(4 years from now) | Active |
FDA has granted several exclusivities to Technegas Kit. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Technegas Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Technegas Kit.
Exclusivity Information
Technegas Kit holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Technegas Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2026 |
US patents provide insights into the exclusivity only within the United States, but
Technegas Kit is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Technegas Kit's family patents as well as insights into
ongoing legal events
on those patents.
Technegas Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Technegas Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 24, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Technegas Kit Generics:
There are no approved generic versions for Technegas Kit as of now.
About Technegas Kit
Technegas Kit is a drug owned by Cyclomedica Australia Pty Ltd. Technegas Kit uses Technetium Tc-99M Labeled Carbon as an active ingredient. Technegas Kit was launched by Cyclomedica in 2023.
Approval Date:
Technegas Kit was approved by FDA for market use on 29 September, 2023.
Active Ingredient:
Technegas Kit uses Technetium Tc-99m Labeled Carbon as the active ingredient. Check out other Drugs and Companies using Technetium Tc-99m Labeled Carbon ingredient
Dosage:
Technegas Kit is available in aerosol form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | AEROSOL | Prescription | INHALATION |